Advancements in Non-Small-Cell Lung Cancer Management
Discover the latest advancements in non-small-cell lung cancer (NSCLC) management, including improved screening techniques, innovative surgical methods, and novel treatment options like targeted therapies and immunotherapy. Learn how these developments are enhancing patient outcomes and survival rates, and the importance of personalized medicine in NSCLC treatment.
ADRIATIC Trial Shows Durvalumab as Promising Treatment for Small Cell Lung Cancer
Dr. Julie Gralow presents interim results of the ADRIATIC trial at the 2024 Plenary Session, focusing on durvalumab as a consolidation treatment for limited-stage small cell lung cancer. Results show significant improvements in overall survival and progression-free survival compared to standard care, potentially changing clinical practice in this field.